|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's range||82.43 - 84.40|
|52-week range||24.55 - 92.97|
|PE ratio (TTM)||11.70|
|Earnings date||2 Nov 2017|
|Dividend & yield||3.30 (3.40%)|
|1y target est||86.18|
Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.
Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.
A three-pronged man-made antibody, created by French drugmaker Sanofi and U.S. scientists, could offer a new way to treat or prevent HIV, following successful tests in monkeys. Plans are under way to try the so-called trispecific antibody in initial human trials before the end of 2018, potentially adding a new weapon in the fight against AIDS, assuming the product proves safe and effective. If all goes well, the three-in-one antibody could be used either as a long-acting treatment or a vaccine, according to Sanofi Chief Scientific Officer Gary Nabel.